-
公开(公告)号：US20170189459A1
公开(公告)日：2017-07-06
申请号：US15304414
申请日：2015-04-14
发明人： Eun Mi SHIN , Gi Duk BAE , Jae Won KIM
CPC分类号： A61K35/76 , A23K10/18 , A23K20/153 , A23K20/195 , A23K50/70 , A23K50/75 , C12N7/00 , C12N2795/10321 , C12N2795/10333
摘要： The present invention relates to a novel bacteriophage ΦCJ24 (KCCM11462P) and a composition comprising the same as an active component. In addition, the present invention relates to a method for preventing and/or treating infectious diseases caused by avian pathogenic E. coli of birds by using the bacteriophage ΦCJ24 (KCCM11462P) or the composition.
-
公开(公告)号：US20170175137A1
公开(公告)日：2017-06-22
申请号：US15127388
申请日：2015-03-25
申请人： Tocagen Inc.
IPC分类号： C12N15/86 , A61K31/7088 , A61K38/21 , A61K38/20 , A61K48/00 , C12N15/113
CPC分类号： C12N15/86 , A61K31/7088 , A61K35/76 , A61K38/2013 , A61K38/217 , A61K48/005 , C12N15/113 , C12N2310/14 , C12N2310/141 , C12N2310/531 , C12N2320/31 , C12N2330/51 , C12N2740/13043
摘要： The disclosure provides vectors for treating cancers, method of producing such vectors and methods of use of the vectors.
-
公开(公告)号：US09682108B2
公开(公告)日：2017-06-20
申请号：US15260207
申请日：2016-09-08
申请人： Crestovo LLC
发明人： Thomas Julius Borody
IPC分类号： A01N63/00 , A01N65/00 , A61K39/08 , A61K35/742 , A61K35/74 , A61K38/48 , A61K35/741 , A61K35/744 , A61K35/747 , A61K36/062 , A61K45/06 , A61K38/14 , A61K31/341 , A61K31/41 , A61K31/495 , A61K31/7034 , A23L2/52 , A61K35/745 , A61K35/38 , A61K35/24 , A61K9/00 , A23C9/123 , A61K9/48 , A23C9/13 , A23L33/135 , A23C9/127 , A61K9/19 , A61K35/37 , A61K31/545 , A61K39/00 , A61K35/76 , A61K31/43 , A61K38/00 , A61K31/7048 , A61K9/50 , A61K39/39 , A61K51/12 , A61K35/00
CPC分类号： A61K35/742 , A23C9/123 , A23C9/127 , A23C9/13 , A23L2/52 , A23L33/135 , A23V2002/00 , A61K9/0031 , A61K9/0053 , A61K9/19 , A61K9/48 , A61K9/4891 , A61K9/50 , A61K9/5005 , A61K9/5078 , A61K31/341 , A61K31/41 , A61K31/43 , A61K31/495 , A61K31/545 , A61K31/7034 , A61K31/7048 , A61K35/24 , A61K35/37 , A61K35/38 , A61K35/74 , A61K35/741 , A61K35/744 , A61K35/745 , A61K35/747 , A61K35/76 , A61K36/062 , A61K38/00 , A61K38/14 , A61K38/4893 , A61K39/00 , A61K39/39 , A61K45/06 , A61K51/1217 , A61K2035/115 , C12N2795/00032 , Y02A50/401 , Y02A50/469 , Y02A50/473 , A61K2300/00
摘要： The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
-
公开(公告)号：US09657312B2
公开(公告)日：2017-05-23
申请号：US14384687
申请日：2012-03-13
申请人： Yeon Soo Kim , Moon Kyung Kang , A Young Song
发明人： Yeon Soo Kim , Moon Kyung Kang , A Young Song
CPC分类号： C12N15/86 , A61K35/76 , A61K38/162 , A61K38/45 , A61K48/00 , C12N2740/10032 , C12N2740/10043 , C12N2740/13045 , C12N2740/13052 , C12N2800/40 , C12N2800/50 , C12Y207/01021
摘要： The present invention provides a vector system in which a MuLV-Gag gene, a MuLV-Pol gene, and a GaLV-Env gene are expressed in two separate vectors. The vector system is capable of inserting a therapeutic gene to these two separate vectors, and in this raged, the size of an inserted gene is not limited and a variety of foreign therapeutic genes may be inserted to the vectors. Accordingly, the foreign therapeutic gene may be delivered in a safe and efficient manner to desired tissue of cells of aberrant proliferation. Therefore, the vector system is applicable in a composition for delivering a gene targeting the aberrantly dividing cells of aberrant proliferation, wherein the composition includes a retrovirus produced by cell line transfection. The vector system is also applicable in a composition for preventing or treating a disease caused by cells of aberrant proliferation of, such as cancer cells.
-
公开(公告)号：US09657277B2
公开(公告)日：2017-05-23
申请号：US14770429
申请日：2014-02-24
发明人： Eun Mi Shin , Gi Duk Bae , Jae Won Kim
IPC分类号： C12N7/00 , A61K35/76 , A01N63/00 , A23L3/3463 , A23L2/44 , A23K10/18 , A23K20/195 , A23K50/30
CPC分类号： C12N7/00 , A01N63/00 , A23K10/18 , A23K20/195 , A23K50/30 , A23L2/44 , A23L3/3463 , A61K35/76 , C12N2795/10221 , C12N2795/10231 , C12N2795/10233
摘要： Provided is a novel bacteriophage ΦCJ19 (KCCM11361P). In addition, the present invention relates to an antibacterial composition including the bacteriophage ΦCJ19 (KCCM11361P) as an active ingredient. Further, the present invention is a method of preventing and/or treating infectious diseases by enterotoxigenic Escherichia coli in animals except for humans using the bacteriophage ΦCJ19 (KCCM11361P) or the antibacterial composition containing the bacteriophage ΦCJ19 (KCCM11361P) as an active ingredient.
-
公开(公告)号：US20170137825A1
公开(公告)日：2017-05-18
申请号：US15319582
申请日：2015-06-16
发明人： Yoshiro Niitsu , Hiroyuki Tanaka
IPC分类号： C12N15/113 , A61K31/713
CPC分类号： C12N15/1137 , A61K31/7088 , A61K31/7105 , A61K31/713 , A61K35/76 , A61K45/06 , A61K48/00 , C12N15/113 , C12N2310/14 , C12N2320/31
摘要： The purpose of the present invention is to provide: a composition for effectively inducing apoptosis and/or proliferation inhibition in cells; and a method in which the composition is used. The present invention relates to: an agent for inducing apoptosis, which contains a GST-π-inhibiting drug and a RB1CC1-inhibiting drug as active ingredients; a pharmaceutical composition which contains the agent; a method for treating a disease associated with an abnormality in apoptosis, in which the agent is used; and others.
-
公开(公告)号：US20170128504A1
公开(公告)日：2017-05-11
申请号：US15249234
申请日：2016-08-26
发明人： Si Yong YANG , Jae Won KIM , Young Wook CHO , Young Sa KIM , Eun Mi SHIN
IPC分类号： A61K35/76 , A23K20/195 , C12R1/91 , C12N7/00 , A01N63/00
CPC分类号： A61K35/76 , A01N63/00 , A23K20/10 , A23K20/147 , A23K20/195 , A23K50/10 , A23K50/30 , A23K50/75 , C12N7/00 , C12N2795/10321 , C12N2795/10331 , C12N2795/10332 , C12R1/91
摘要： The present invention relates to a novel bacteriophage having a specific bactericidal activity against salmonella, a composition for the prevention or treatment of infectious diseases comprising the bacteriophage as an active ingredient, an antibiotic comprising the bacteriophage as an active ingredient, an animal feed or drinking water comprising the bacteriophage as an active ingredient, and a sanitizer or cleaner comprising the bacteriophage as an active ingredient. The novel bacteriophage of the present invention has a specific bactericidal activity against Salmonella choleraesuis, Salmonella typhimurium, Salmonella derby, Salmonella infantis or Salmonella newport with no influences on beneficial bacteria, as well as excellent acid- and heat-resistance and desiccation tolerance. Therefore, the novel bacteriophage can be used for the prevention or treatment of salmonellosis or salmonella food poisoning, which is an infectious disease caused by Salmonella choleraesuis, Salmonella typhimurium, Salmonella derby, Salmonella infantis or Salmonella newport, and also widely used in animal feeds, drinking water for livestock, sanitizers, and cleaners.
-
公开(公告)号：US09623058B2
公开(公告)日：2017-04-18
申请号：US14356869
申请日：2012-11-07
发明人： Ying Jia
CPC分类号： A61K35/76 , A61K9/0014 , A61K9/0043 , C12N7/00 , C12N2795/10121 , C12N2795/10131
摘要： The present invention provides a bacteriophage with effective antibacterial activity against Staphylococcus strains and in particular MRSA. There is also provided a pharmaceutical composition comprising said bacteriophage and a method of treating a bacterial infection using a composition comprising said bacteriophage.
-
公开(公告)号：US09616119B2
公开(公告)日：2017-04-11
申请号：US14667512
申请日：2015-03-24
IPC分类号： A61K39/245 , A61K39/12 , C07K14/005 , C12N7/00 , A61K39/00
CPC分类号： A61K39/245 , A61K39/12 , A61K2039/5254 , A61K2039/545 , C07K14/005 , C12N7/00 , C12N2710/16621 , C12N2710/16622 , C12N2710/16634 , C12N2710/16652 , C12N2710/16662 , C12N2710/16671 , A61K35/763 , A61K2039/53 , A61K35/76 , C12N2710/16632 , C12N2710/16643 , C07K14/035
摘要： A mutant HSV-1 (referred to herein as KOS-NA) was generated. KOS-NA contains novel mutations in the UL39 gene, which encodes for a protein that is a large subunit of ribonucleotide reductase (i.e., ICP6). These UL39 mutations were found to alter two amino acids in ICP6 (R950H and L393P) and are responsible for attenuation of KOS-NA in vivo, and resulted in diminished ICP6 protein levels. These novel UL39 mutations regulate the expression and/or stability of ICP6 and severely impact HSV-1 pathogenesis. Mutant HSV viruses containing these mutations appear to protect against HSV infection and can serve as therapeutic vaccines to help combat preexisting HSV infection in infected individuals.
-
公开(公告)号：US09610308B2
公开(公告)日：2017-04-04
申请号：US15178539
申请日：2016-06-09
申请人： Crestovo LLC
发明人： Thomas Julius Borody
IPC分类号： A61K39/00 , A61K39/38 , A61K39/02 , A61K39/08 , A61K39/108 , A61K35/741 , A61K35/74 , A61K38/48 , A61K35/742 , A61K35/744 , A61K35/747 , A61K36/062 , A61K45/06 , A61K38/14 , A61K31/341 , A61K31/41 , A61K31/495 , A61K31/7034 , A23L2/52 , A61K35/745 , A61K35/38 , A61K35/24 , A61K9/00 , A23C9/123 , A61K9/48 , A23C9/13 , A23L33/135 , A23C9/127 , A61K31/545 , A61K35/76 , A61K31/43 , A61K38/00 , A61K31/7048 , A61K9/50 , A61K39/39 , A61K51/12 , A61K35/00
CPC分类号： A61K35/742 , A23C9/123 , A23C9/127 , A23C9/13 , A23L2/52 , A23L33/135 , A23V2002/00 , A61K9/0031 , A61K9/0053 , A61K9/19 , A61K9/48 , A61K9/4891 , A61K9/50 , A61K9/5005 , A61K9/5078 , A61K31/341 , A61K31/41 , A61K31/43 , A61K31/495 , A61K31/545 , A61K31/7034 , A61K31/7048 , A61K35/24 , A61K35/37 , A61K35/38 , A61K35/74 , A61K35/741 , A61K35/744 , A61K35/745 , A61K35/747 , A61K35/76 , A61K36/062 , A61K38/00 , A61K38/14 , A61K38/4893 , A61K39/00 , A61K39/39 , A61K45/06 , A61K51/1217 , A61K2035/115 , C12N2795/00032 , Y02A50/401 , Y02A50/469 , Y02A50/473 , A61K2300/00
摘要： The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
-
-
-
-
-
-
-
-
-
搜索结果
1167 条记录 (耗时 0.036 秒)
